nach oben

Erschienen in:

01.01.2010 | Original Article—Liver, Pancreas, and Biliary Tract

Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis

verfasst von: Annarosa Floreani, Roberta Lazzari, Veronica Macchi, Andrea Porzionato, Angela Variola, Davide Colavito, Alberta Leon, Maria Guido, Vincenzo Baldo, Raffaele De Caro, Nora V. Bergasa

Erschienen in: Journal of Gastroenterology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The endocannabinoid system (EC) has emerged as a crucial mediator in a variety of pathophysiological conditions.

Aims

To evaluate: (1) whether the EC system is activated in the livers of patients with primary biliary cirrhosis (PBC); (2) if genetic variations in human EC receptor genes (CB1 and CB2) may be associated with a different phenotypic expression of the disease and response to therapy.

Methods

The expression of CB1 and CB2 receptors was studied by immunohistochemistry in liver biopsy specimens from 13 patients with PBC, and CB1 and CB2 mRNA expression was studied by real-time polymerase chain reaction testing (RT-PCR) in liver samples. In addition, genetic polymorphisms in the EC receptor gene were sought in 68 patients with PBC from Italy, 84 patients who were residents of the United States (US), and 70 controls matched for sex, age, and for geographical area with the Italian PBC patients. Genomic DNA was extracted from peripheral venous blood leucocytes with standard methods. PCR was used to amplify the coding regions of the CB1 and CB2 genes with specific primers.

Results

CB1 was markedly expressed in hepatocytes and biliary epithelial cells in the livers of patients with PBC; conversely in control liver samples, it was virtually absent. CB2 was expressed in hepatocytes and in cholangiocytes, whereas it was absent from mesenchymal cells. The mRNA of both CB1 and CB2 was detected in the PBC liver samples, as demonstrated by RT-PCR. The CB1 polymorphism (1359 G/A) was present in 26.5% of Italian patients, in 22.9% of healthy controls, and in 27.4% of patients from the US (p = n.s.). The CB2 polymorphism (188–189 AA/GG) was present in 24.4 versus 30.4% of Italian and US patients with PBC, respectively, and in 28.0% of Italian controls samples (p = n.s.). Logistic regression analysis showed that advanced histological stage and the lack of response to ursodeoxycholic acid treatment were significantly correlated with the CB1 polymorphism.

Conclusions

The EC system is markedly up-regulated in the livers of patients with PBC and it may exert a role regulating adaptive mechanisms in cholestasis.

Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771–84.CrossRefPubMed

Woods SC. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med. 2007;120:S9–17.CrossRefPubMed

Julien B, Grenard P, Teixeira-Clerc F, Tran Van Nhieu J, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–55.CrossRefPubMed

Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol. 2008;20(suppl 1):47–52.CrossRefPubMed

Siegmund SD, Shwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G357–62.CrossRefPubMed

Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42:63–71.CrossRefPubMed

Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–11.CrossRefPubMed

Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486–96.CrossRefPubMed

Mechoulam M, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108:1–13.CrossRefPubMed

10.

Norrod AG, Puffenbarger RA. Genetic polymorphisms of the endocannabinoid system. Chem Biodivers. 2007;4:1926–32.CrossRefPubMed

11.

Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes. 1999;13:321–5.CrossRefPubMed

12.

Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol. 2005;78:231–8.CrossRefPubMed

13.

Berdyshev EV. Cannabinoid receptors and the regulation of the immune response. Chem Phys Lipids. 2000;108:169–90.CrossRefPubMed

14.

Neef GW, O’Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117–9.CrossRef

15.

Floreani A, Carderi I, Variola A, Rizzotto ER, Nicol J, Bergasa NV. A novel multidrug resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology. 2006;43:1152–4.CrossRefPubMed

16.

Wei LX, Floreani A, Variola A, El Younis C, Bergasa NV. A study of the mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venerol. 2008;88:323–6.PubMed

17.

Scheuer PJ. Primary biliary cirrhosis. Proc Roy Soc Med. 1967;60:1257–60.PubMed

18.

Parés A, Llorenc Caballeria, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–20.CrossRefPubMed

19.

Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57:1140–55.CrossRefPubMed

20.

Fernandez-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutierrez ML, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 2004;24:477–83.CrossRefPubMed

21.

Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671–6.CrossRefPubMed

22.

Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007;21:1788–800.CrossRefPubMed

23.

Stella N. Endocannabinoid signalling in microglial cells. Neuropharmacology. 2009;56(suppl. 1):244–53.CrossRefPubMed

24.

Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol. 1999;56:1362–9.PubMed

25.

Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–305.PubMed

26.

Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med. 2008;29:50–7.CrossRefPubMed

27.

Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–77.CrossRefPubMed

28.

Leuchner M, Dietrich CF, You T, Seidl C, Raedle J, Hermann G, et al. Characterization of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut. 2000;46:121–6.CrossRef

29.

Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007;152:734–43.CrossRefPubMed

30.

Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferators-activated receptor γ with the endocannabinoid system. Br J Pharmacol. 2007;151:1343–51.CrossRefPubMed

31.

Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006;3:231–51.CrossRefPubMed

Titel: Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis
verfasst von: Annarosa Floreani
Roberta Lazzari
Veronica Macchi
Andrea Porzionato
Angela Variola
Davide Colavito
Alberta Leon
Maria Guido
Vincenzo Baldo
Raffaele De Caro
Nora V. Bergasa
Publikationsdatum: 01.01.2010
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 1/2010
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-009-0122-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis